uniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Says

uniQure submitted a Biologics License Application (BLA) to the FDA seeking accelerated approval for ifezuntirgene inilparvovec (AMT-130), its investigational Huntington’s gene therapy. The filing is a positive regulatory milestone that increases the probability of an FDA decision ahead of a full review timeline. Overall, the news is likely supportive for near-term sentiment in QURE as it advances toward potential approval.